Max Wolff is a psychologist and psychotherapist. He currently serves as the Head of Psychotherapy Training and Research at the MIND Foundation. His research is concerned with the psychotherapeutic mechanisms and contextual conditions of psychedelic-occasioned psychological change, and aims to make the findings of psychotherapy research applicable to the practice of psychedelic therapy. As a psychotherapist, Max works with cognitive-behavioral, acceptance-based, and emotion-focused approaches. He directs the MIND Foundation’s APT Program, an international training in psychedelic-augmented psychotherapy for psychotherapists, psychiatrists, and other mental health professionals. He is also involved as a researcher and study therapist in the EPIsoDE trial, a phase 2b clinical trial investigating the safety and efficacy of psilocybin for treatment-resistant depression at the Central Institute of Mental Health (CIMH) Mannheim, Germany, and Charité University Medicine Berlin.